123 related articles for article (PubMed ID: 37801361)
1. Initial investigation of using Norwegian health data for the purpose of external comparator arms - an example for non-small cell lung cancer.
Børø S; Thoresen S; Boge Brant S; Helland Å
Acta Oncol; 2023 Dec; 62(12):1642-1648. PubMed ID: 37801361
[TBL] [Abstract][Full Text] [Related]
2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
3. Comparison of data from the Norwegian Patient Register and the Cancer Registry of Norway.
Bakken IJ; Gystad SO; Christensen ØO; Huse UE; Larønningen S; Nygård J; Holmstrøm L; Johannesen TB; Møller B; Larsen IK
Tidsskr Nor Laegeforen; 2012 Jun; 132(11):1336-40. PubMed ID: 22717858
[TBL] [Abstract][Full Text] [Related]
4. Replication of Oncology Randomized Trial Results using Swedish Registry Real World-Data: A Feasibility Study.
Jemielita T; Widman L; Fox C; Salomonsson S; Liaw KL; Pettersson A
Clin Pharmacol Ther; 2021 Dec; 110(6):1613-1621. PubMed ID: 34549809
[TBL] [Abstract][Full Text] [Related]
5. Real-world data from the Portuguese Nivolumab Expanded Access Program (EAP) in previously treated Non Small Cell Lung Cancer (NSCLC).
Figueiredo A; Almeida MA; Almodovar MT; Alves P; Araújo A; Araújo D; Barata F; Barradas L; Barroso A; Brito U; Camacho E; Canário D; Cardoso T; Chaves A; Costa L; Cunha J; Duarte J; Estevinho F; Felizardo M; Fernandes JP; Ferreira L; Ferreira L; Fidalgo P; Freitas C; Garrido P; Gil N; Hasmucrai D; Jesus E; Lopes JA; de Macedo JE; Meleiro A; Neveda R; Nogueira F; Pantorotto M; Parente B; Pego A; Rocha M; Roque J; Santos C; Saraiva J; Silva E; Silva S; Simões S; Soares M; Teixeira E; Timóteo T; Hespanhol V
Pulmonology; 2020; 26(1):10-17. PubMed ID: 31630986
[TBL] [Abstract][Full Text] [Related]
6. Developing real-world comparators for clinical trials in chemotherapy-refractory patients with gastric cancer or gastroesophageal junction cancer.
Chau I; Le DT; Ott PA; Korytowsky B; Le H; Le TK; Zhang Y; Sanchez T; Maglinte GA; Laurie M; Abraham P; Patel D; Shangguan T
Gastric Cancer; 2020 Jan; 23(1):133-141. PubMed ID: 31549264
[TBL] [Abstract][Full Text] [Related]
7. Overall Survival With Second-Line Pembrolizumab in Patients With Non-Small-Cell Lung Cancer: Randomized Phase III Clinical Trial Versus Propensity-Adjusted Real-World Data.
Jemielita T; Li XN; Piperdi B; Zhou W; Burke T; Chen C
JCO Clin Cancer Inform; 2021 Jan; 5():56-65. PubMed ID: 33439727
[TBL] [Abstract][Full Text] [Related]
8. Cisplatin/carboplatin + etoposide + vinorelbine in advanced non-small-cell lung cancer: a multicentre randomised trial. Gruppo Oncologico Campano.
Comella P; Frasci G; De Cataldis G; Panza N; Cioffi R; Curcio C; Belli M; Bianco A; Ianniello G; Maiorino L; Della Vittoria M; Perchard J; Comella G
Br J Cancer; 1996 Dec; 74(11):1805-11. PubMed ID: 8956797
[TBL] [Abstract][Full Text] [Related]
9. Real-world progression, treatment, and survival outcomes during rapid adoption of immunotherapy for advanced non-small cell lung cancer.
Khozin S; Miksad RA; Adami J; Boyd M; Brown NR; Gossai A; Kaganman I; Kuk D; Rockland JM; Pazdur R; Torres AZ; Zhi J; Abernethy AP
Cancer; 2019 Nov; 125(22):4019-4032. PubMed ID: 31381142
[TBL] [Abstract][Full Text] [Related]
10. KRAS G12C Mutant Non-Small Cell Lung Cancer Linked to Female Sex and High Risk of CNS Metastasis: Population-based Demographics and Survival Data From the National Swedish Lung Cancer Registry.
Isaksson J; Berglund A; Louie K; Willén L; Hamidian A; Edsjö A; Enlund F; Planck M; Vikström A; Johansson M; Hallqvist A; Wagenius G; Botling J
Clin Lung Cancer; 2023 Sep; 24(6):507-518. PubMed ID: 37296038
[TBL] [Abstract][Full Text] [Related]
11. Replication of Overall Survival, Progression-Free Survival, and Overall Response in Chemotherapy Arms of Non-Small Cell Lung Cancer Trials Using Real-World Data.
Ton TGN; Pal N; Trinh H; Mahrus S; Bretscher MT; Machado RJM; Sadetsky N; Chaudhary N; Lu MW; Riely GJ
Clin Cancer Res; 2022 Jul; 28(13):2844-2853. PubMed ID: 35511917
[TBL] [Abstract][Full Text] [Related]
12. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.
Garassino MC; Cho BC; Kim JH; Mazières J; Vansteenkiste J; Lena H; Corral Jaime J; Gray JE; Powderly J; Chouaid C; Bidoli P; Wheatley-Price P; Park K; Soo RA; Huang Y; Wadsworth C; Dennis PA; Rizvi NA;
Lancet Oncol; 2018 Apr; 19(4):521-536. PubMed ID: 29545095
[TBL] [Abstract][Full Text] [Related]
13. Emulating Control Arms for Cancer Clinical Trials Using External Cohorts Created From Electronic Health Record-Derived Real-World Data.
Tan K; Bryan J; Segal B; Bellomo L; Nussbaum N; Tucker M; Torres AZ; Bennette C; Capra W; Curtis M; Miksad RA
Clin Pharmacol Ther; 2022 Jan; 111(1):168-178. PubMed ID: 34197637
[TBL] [Abstract][Full Text] [Related]
14. Using clinical cancer registry data for estimation of quality indicators: Results from the Norwegian breast cancer registry.
Hartmann-Johnsen OJ; Kåresen R; Schlichting E; Naume B; Nygård JF
Int J Med Inform; 2019 May; 125():102-109. PubMed ID: 30914174
[TBL] [Abstract][Full Text] [Related]
15. A phase II randomized trial evaluating gefitinib intercalated with pemetrexed/platinum chemotherapy or pemetrexed/platinum chemotherapy alone in unselected patients with advanced non-squamous non-small cell lung cancer.
Yu H; Zhang J; Wu X; Luo Z; Wang H; Sun S; Peng W; Qiao J; Feng Y; Wang J; Chang J
Cancer Biol Ther; 2014 Jul; 15(7):832-9. PubMed ID: 24755888
[TBL] [Abstract][Full Text] [Related]
16. SWOG S0709: Randomized Phase II Trial of Erlotinib versus Erlotinib Plus Carboplatin/Paclitaxel in Patients with Advanced Non-Small Cell Lung Cancer and Impaired Performance Status as Selected by a Serum Proteomics Assay.
Lara PN; Moon J; Hesketh PJ; Redman MW; Williamson SK; Akerley WL; Hirsch FR; Mack PC; Gandara DR
J Thorac Oncol; 2016 Mar; 11(3):420-5. PubMed ID: 26725184
[TBL] [Abstract][Full Text] [Related]
17. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
18. Randomised phase II trial of 4 dose levels of single agent docetaxel in performance status (PS) 2 patients with advanced non-small cell lung cancer (NSCLC): DOC PS2 trial. Manchester lung cancer group.
Califano R; Griffiths R; Lorigan P; Ashcroft L; Taylor P; Burt P; Lee L; Chittalia A; Harris M; Faivre-Finn C; Thatcher N; Blackhall F
Lung Cancer; 2011 Sep; 73(3):338-44. PubMed ID: 21296449
[TBL] [Abstract][Full Text] [Related]
19. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial.
Shaverdian N; Lisberg AE; Bornazyan K; Veruttipong D; Goldman JW; Formenti SC; Garon EB; Lee P
Lancet Oncol; 2017 Jul; 18(7):895-903. PubMed ID: 28551359
[TBL] [Abstract][Full Text] [Related]
20. The cancer registry as an ally in monitoring treatment effectiveness.
Costa FA; Ramos C; Murteira R; Almodovar T; Passos-Coelho JL; Carvalho MI; Costa L; Brito MJ; Ramos S; Ferreira M; Miranda AC
Pulmonology; 2019; 25(1):3-8. PubMed ID: 30361162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
